I would not claim that, obviously no one, including you, knows exactly. It did seem strange that he never left where he was working for Merck to move to NWBO HQ. But no one knows…
I do think his role had more to do with helping them with regulatory strategy and refusing from just one or a given cancer to a more general approach, and we may or may not see more on that, and I also think he likely also assisted them on managing the conclusion of DCVax-L. He likely had much expertise that was useful. But he probably knew that time that it was not going to be a 6 month or 1 year opportunity with a huge payout after a year or two. That was a few years ago now. So not sure why he’s being discussed. He very well could have brought back info to Merck. Coordination between companies does not have to be highly formalized when they are doing due diligence only.
Bullish
Market Data 
Markets 
AI
